Clover Health Investments (CLOV) is "fully valued" after "a good job" improving core operations and medical costs, UBS Securities said Monday in a report initiating coverage of the company with a neutral rating.
Clover Health's Medicare Advantage star rating rose to 4.0 from 3.5, according to preliminary data indicated by the Centers for Medicare & Medicaid Services, boosting prospect for enrollment and revenue growth, UBS said.
In 2025, UBS projects revenue of $1.6 billion with $1.8 billion in 2026 with enrollment growth of 10% next year and 8% in 2026. "While positive on the company's trajectory and improvement, we see this as appropriately captured in the stock price today," the report said.
Clover Health's enrollment growth in its key state of New Jersey showed the company is only outperforming the market in a few core counties while lagging behind in most others, posing a near-term "headwind" to growth, UBS said.
UBS has a price target of $4 on Clover Health.
Shares of Clover Health slumped 8.8% in recent trading Monday.
Price: 3.6850, Change: -0.3550, Percent Change: -8.7871
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。